S&P 5007,651.54▼0.2% Nasdaq26,861.06▲0.2% Dow50,906.05▼0.9% Russell 2K2,796.86▼0.4% 10-Yr5.29%+4bp VIX16.34+0.30 WTI$90.46▲1.2% Gold$4,189.00▲0.2% EUR/USD1.133▼0.3% BTC$84,852▲0.0% Nikkei65,481▼0.6%
At close · Wed, Sep 30, 2026
Daily Market Updates.

Earnings

Home›Earnings›Previews›Lilly and Novo are developing amylin drugs after GLP-1s

Lilly and Novo are developing amylin drugs after GLP-1s

Reported · Written up by our desk · Previews

CNBC reports that Eli Lilly and Novo Nordisk are developing new amylin-based drugs aimed at treating obesity and diabetes.

The outlets say the companies are targeting amylin as a separate biological lever following GLP-1 focused therapies.

← Newer storyG7 plans release of up to 100 million barrels to ease diesel shortages

More like this

EarningsAST SpaceMobile ships next BlueBird satellites as launch timing stays uncertain
EarningsCorning and AT&T finalize multi-year fiber supply deal worth over $3B
EarningsTarget cuts prices on about 2,000 items ahead of the holidays
EarningsNIO to sell 30% stake in battery-swapping unit to Geely
EarningsInhibrx CEO buys $3.6 million in shares ahead of FDA decision

Sources

CNBC MarketsWhy Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
CNBC WorldWhy Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.